TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02365766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: In this dose-finding cohort, pembrolizumab (MK-3475) will be administered (cisplatin-eligible patients only) at starting dose 200mg IV every 21 days for 4 cycles to determine RP2D. Once MTD is established in phase Ib, pembrolizumab will be administered on phase II cohorts I and II at RP2D every 21 days for 5 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: In this dose-finding cohort, pembrolizumab (MK-3475) will be administered (cisplatin-eligible patients only) at starting dose 200mg IV every 21 days for 4 cycles to determine RP2D. Once MTD is established in phase Ib, pembrolizumab will be administered on phase II cohorts I and II at RP2D every 21 days for 5 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: In this dose-finding cohort, pembrolizumab (MK-3475) will be administered (cisplatin-eligible patients only) at starting dose 200mg IV every 21 days for 4 cycles to determine RP2D. Once MTD is established in phase Ib, pembrolizumab will be administered on phase II cohorts I and II at RP2D every 21 days for 5 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: For cisplatin-eligible patients on phase Ib and phase II cohort 1, gemcitabine 1000mg/m2 IV, D1 and D8 every 21 days for 4 cycles. For cisplatin-ineligible patients on phase II cohort II, gemcitabine 1000mg/m2 will be administered D1, D8 and D15 every 28 days for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: For cisplatin-eligible patients on phase Ib and phase II cohort 1, gemcitabine 1000mg/m2 IV, D1 and D8 every 21 days for 4 cycles. For cisplatin-ineligible patients on phase II cohort II, gemcitabine 1000mg/m2 will be administered D1, D8 and D15 every 28 days for 3 cycles.
Study: NCT02938520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/DTG/3TC STR - Tablet
Description: It is a purple, biconvex, oval, tablet debossed with 572 Tri on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate.
Study: NCT04411212

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Mock embryo transfer is performed without injecting anything inside the uterus.
Study: NCT02619318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balancing Everyday Life (BEL)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual (generally standard occupational therapy)
Study: NCT03832153

Intervention type: PROCEDURE
Intervention: thrombus aspiration
Description: Thrombus aspiration will be performed by experienced interventional cardiologists according to standard practices, as previously described. The intracoronary blood samples will be collected as well during the same procedure and- along with peripheral blood samples- they will be analyzed for the presence of specific miRNAs. The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using the micro/nano-CT scanners.

Intervention type: PROCEDURE
Intervention: thrombus aspiration
Description: Thrombus aspiration will be performed by experienced interventional cardiologists according to standard practices, as previously described. The intracoronary blood samples will be collected as well during the same procedure and- along with peripheral blood samples- they will be analyzed for the presence of specific miRNAs. The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using the micro/nano-CT scanners.
Study: NCT02750904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental plus Nicotine Replacement Therapy
Description: Behavioral: Experimental plus Nicotine Replacement Therapy will be built to specifically address challenges of smoking cessation for individuals with bipolar disorder.~Includes four in person and four phone visits.~Therapy information is withheld to protect the integrity of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control plus Nicotine Replacement Therapy
Description: Includes four in-person and four phone visits
Study: NCT03569865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual Stimulation
Description: A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual Stimulation
Description: A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Audiovisual Stimulation
Description: A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study.
Study: NCT02365766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: For cisplatin-eligible patients on phase Ib and phase II cohort 1, gemcitabine 1000mg/m2 IV, D1 and D8 every 21 days for 4 cycles. For cisplatin-ineligible patients on phase II cohort II, gemcitabine 1000mg/m2 will be administered D1, D8 and D15 every 28 days for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: For cisplatin-eligible patients, cisplatin 70mg/m2 IV will be administered D1 every 21 days for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: For cisplatin-eligible patients, cisplatin 70mg/m2 IV will be administered D1 every 21 days for 4 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Consolidative Surgery
Description: Following completion of treatment, subjects will then have surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Consolidative Surgery
Description: Following completion of treatment, subjects will then have surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
Study: NCT01976936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Lovastatin
Description: 80 mg daily for 3 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Lovastatin
Description: 640 mg daily for 3 days
Study: NCT02702518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhDNase I
Description: rhDNase I, 0.1% eye drops 4 times a day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Drug vehicle 4 times a day for 8 weeks
Study: NCT03661489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: For induction and maintenance of general anesthesia
Study: NCT00618449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromcyin
Description: 1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given 30 days apart; at Day 0 \& Day 30 for a total of 2 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given at Day 30 for a total of 1 dose.
Study: NCT02273557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER (new formulation I - low)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER (new formulation III - medium)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER (new formulation II - high)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asasantin ER (present commercial formulation)
Study: NCT04096326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: AGN-151586 solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: AGN-151586 solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: AGN-151586 solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: AGN-151586 solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: AGN-151586 solution for injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection.
Study: NCT02938520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG Tablet
Description: It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with SV 572 on one side and 50 on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate.
Study: NCT01084434

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Description: Bifidobacterium lactis HN019 10\^9 CFU/day 1 sachet once a day for 7 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: prebiotic
Description: Galactooligosaccharide 5.5 g/day 1 sachet once a day for 7 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: (Bifidobacterium lactis 10\^9 CFU + Galactooligosaccharide 5.5g) / day - 1 sachet once a day for 7 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin 5.5g/day - 1 sachet once a day for 7 weeks
Study: NCT04555304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH903 + Paclitaxel
Description: KH903 4 mg/kg will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Paclitaxel
Description: Placebo will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
Study: NCT03595163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.
Study: NCT02019082

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation (BTL-5000 series, United Kingdom)
Description: Direct current ES

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the intervention procedure was the same as that the ES group, but the current intensity was zero
Study: NCT03116321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eslicarbazepine acetate (ESL)
Description: Oral Tablet of 800 mg and 200 mg of ESL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Description: Oral Tablet of 800 mg and 200 mg of ESL
Study: NCT04096326

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection.
Study: NCT00004418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyceryl trierucate/glyceryl trioleate
Description: Administration of glyceryl trierucate/glyceryl trioleate
Study: NCT02072720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: patients will receive bevacizumab (3mg/kg/wk) starting from the identified induction time point of VEGF expression
Study: NCT03755284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sacral Massage
Description: ● In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour.
Study: NCT02503631

Intervention type: DEVICE
Intervention: Stool Sample Collection Kit
Description: Stool sample collection kit
Study: NCT02472119

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rusks made of wheat flour enzymatically treated
Description: 100 g of rusks obtained from commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: rusks made of wheat flour not enzimatically modified
Description: 100 g of rusks obtained from commercial wheat flour NOT enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten-free diet
Description: gluten-free diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Description: gluten-free diet
Study: NCT04367025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab: 200mg,iv drip for 1h,d1,q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: S-1:40\~60mg Bid, d1\~14, q3w;
Study: NCT04729556

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sericin and chitosan cream
Description: A novel film-forming cream containing sericin and chitosan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sericin and chitosan cream
Description: A novel film-forming cream containing sericin and chitosan
Study: NCT02084784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Subcutaneous injection around the areola with 2-4 points Indocyanine green with 1ml of 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylene blue
Description: Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1%
Study: NCT02346500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transrectal Ultrasound
Description: The TRUS and TRUS-Robot will be used to record ultrasound images during PVP. The PVP procedure will be conducted as usual, without using the ultrasound for guiding the intervention.
Study: NCT02991937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam
Description: 24 hours of IV antibiotic administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam
Description: 24 hours of IV antibiotic administration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Treatment
Description: Appendectomy
Study: NCT00414960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Description: 500 mg po QD for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po QD for 6 months
Study: NCT03259490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin/linagliptin/metformin HCl
Description: Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Once daily
Study: NCT03116321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Description: Oral Tablet of 800 mg and 200 mg of ESL
Study: NCT03259490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl
Description: Once daily
Study: NCT02942316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupil dilation reflex measurement
Description: Pupillometry (PDR) at four standardized times perioperatively~* after induction, before opioid administration~* after opioid administration, steady state~* surgical incision~* end of procedure
Study: NCT02024204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 230mcg for 3 Months

Intervention type: DRUG
Group type: OTHER
Intervention: Current Treatment or no treatment
Description: Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
Study: NCT03889652

Intervention type: DIAGNOSTIC_TEST
Intervention: Oct scans
Description: Oct scans to assess thickness of RNFL and GCC before and after cataract extraction surgery in both groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Oct scans
Description: Oct scans to assess thickness of RNFL and GCC before and after cataract extraction surgery in both groups
Study: NCT00948350

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: awake intubation
Description: two anesthesia techniques
Study: NCT02894866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen
Description: The hyperbaric oxygen treatment will be administered for 60 min in a baby hyperbaric oxygen chamber pressured with 100% oxygen to 1.5 to 1.8 atm absolute (ATA) and a constant oxygen flow was given to maintain the oxygen. concentration in the chamber at 80% or greater.The treatment will be administered once a day within 7 days after birth, 7 days is a course of treatment, at least for 4 courses.
Study: NCT02024204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol 21mcg for 3 Months
Study: NCT03455309

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-3A
Description: Single dose administered by intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose administered by intramuscular injection
Study: NCT03420716

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yogurt

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yogurt
Study: NCT00815906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: IV, Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: IV, Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: SC, Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: SC, Single dose
Study: NCT02240537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Drug: Sargramostim (GM-CSF) Other Names: Leukine Sargramostim (250 ug vial) is reconstituted with 0.5 ml of Sterile Water for Injection. Subjects will receive 0.5 ml intradermally (250 µg) near the arm pit or inside of thigh.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-MPI-03
Description: Other Names: Multi-peptide immunotherapy (MPI) is comprised of 3 cytotoxic T-cell epitopes derived from oncofetal antigen. There are 3 dose levels of study vaccine planned to be tested, starting at 0.25 mg each peptide (0.75 mg total peptide dose), then 0.5 mg of each peptide (1.5 mg total) and finally 1 mg each peptide (3 mg total). At the starting dose of 0.75 mg, the BB MPI 03-15 mg vial is used and 100 ul is administered; at the 1.5 mg dose, 200 ul of the BB MPI 03-15 mg vial is used; at the 3 mg dose, 200 ul of the BB MPI 03-30 mg is used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide
Description: Drug: Montanide Other Names: mineral oil, USP BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3 minutes after sargramostim administration.~Subjects and the injection sites are to be monitored for 1 hour after sargramostim and BB-MPI-03 emulsion administration.
Study: NCT00740168

Intervention type: DRUG
Intervention: bevacizumab treatment
Description: single infusion 10 mg/kg
Study: NCT00647868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: Intranasal testosterone, 7.6 mg (3.8 mg in each nostril) per application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: Intranasal testosterone, 7.6 mg (3.8 mg in each nostril) per application
Study: NCT03188679

Intervention type: DEVICE
Group type: OTHER
Intervention: amniocentesis
Description: mRNA sequencing on amniotic fluid samples of fetuses after maternal seroconversion for CMV
Study: NCT02995590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized He3
Description: Hyperpolarized Helium can be used as a Contrast Agent for Lung Images using MRI.
Study: NCT01638611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HIP2B
Description: Total daily doses of 60, 120, 240, 480, and 720 mg are planned in five separate dosing cohorts. Single or split dose (depending on dose volume) will be given by subcutaneous injection in the abdomen to six subjects per dosing cohort.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.
Study: NCT04501679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.